<|ref|>figure_title<|/ref|><|det|>[[51, 89, 476, 115]]<|/det|>
PK Analysis of Blood Samples (Plasma  \( \mu \) g/mL) for  \( ^{89} \) Zr-Nivolumab Carrier-Added Studies in NHPs.

<|ref|>table<|/ref|><|det|>[[53, 117, 475, 227]]<|/det|>
<table><tr><td></td><td>Carrier-Added 1 mg/kg \( ^{a} \)</td><td>Carrier-Added 3 mg/kg \( ^{a} \)</td></tr><tr><td>Actual injected mass</td><td>0.95 mg/kg</td><td>2.81 mg/kg</td></tr><tr><td>Before infusion</td><td>&lt;0.200</td><td>&lt;0.200</td></tr><tr><td>15 min after infusion</td><td>18.9</td><td>62.4</td></tr><tr><td>24 h (1 days) after infusion</td><td>11.5</td><td>41.1</td></tr><tr><td>96 h (4 days) after infusion</td><td>10.7</td><td>27.2</td></tr><tr><td>144 h (6 days) after infusion</td><td>8.29</td><td>25.6</td></tr><tr><td>192 h (8 days) after infusion</td><td>5.69</td><td>21.2</td></tr></table>

<|ref|>text<|/ref|><|det|>[[58, 231, 440, 243]]<|/det|>
 \( ^{a} \)  Targeted injection dose: mg  \( ^{89} \) Zr-nivolumab and nivolumab/kg of NHP.

<|ref|>sub_title<|/ref|><|det|>[[51, 259, 146, 272]]<|/det|>
## 4. Conclusion

<|ref|>text<|/ref|><|det|>[[49, 285, 480, 484]]<|/det|>
These studies demonstrate that the anti-PD-1 HuMAb nivolumab can be modified with the bifunctional chelator DFO and radiolabeled with  \( {}^{89} \) Zr with good purity and radiochemical yield. The in vivo NIHP imaging with tracer only  \( {}^{89} \) Zr-nivolumab indicates specific biodistribution to the spleen. Carrier-added studies of 1 and 3 mg/kg show spleen uptake can be blocked by a co-administration of excess nivolumab. In all studies, tracer distribution to other organs was consistent with the excretion pathways of antibodies, with primary clearance through the liver. This report details the first ever radiolabeling and PET imaging of nivolumab in a non-human primate. The success of this methodology adds to the body of knowledge encompassing the in vivo biodistribution of immune-oncology agents. Approaches described herein could readily be translated to the clinic for future studies of immunooncology modifying molecules.

<|ref|>sub_title<|/ref|><|det|>[[51, 500, 255, 514]]<|/det|>
## Conflict of interest statement

<|ref|>text<|/ref|><|det|>[[50, 527, 478, 554]]<|/det|>
All authors in this manuscript are employed by Bristol-Myers Squibb Co.

<|ref|>sub_title<|/ref|><|det|>[[51, 569, 186, 583]]<|/det|>
## Acknowledgements

<|ref|>text<|/ref|><|det|>[[49, 595, 479, 675]]<|/det|>
The authors wish to thank Bozena M. Abramczyk, Lin Cheng, Mian Gao, Adam Jardel, Frank Marsilio, Kristina Moore, and John Newitt for providing hPD1(25-167)-Myc-TVMV-His protein. Yun Wang and Hui Wei for mass spectroscopy. Harold Malone, Thomas Petrone, and Haiying Tang for providing imaging support and Triton Iran for radio-analytical support.

<|ref|>sub_title<|/ref|><|det|>[[51, 692, 190, 706]]<|/det|>
## Supplementary data

<|ref|>text<|/ref|><|det|>[[50, 718, 478, 745]]<|/det|>
Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.bmc.2017.07.066.

<|ref|>sub_title<|/ref|><|det|>[[52, 760, 128, 773]]<|/det|>
## References

<|ref|>text<|/ref|><|det|>[[58, 785, 477, 805]]<|/det|>
1. Coffelt SB, de Visser KE. Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends Immunol. 2015;36:198–216.

<|ref|>text<|/ref|><|det|>[[58, 806, 477, 825]]<|/det|>
2. Waldmann TA. Immunotherapy: past, present and future. Nat Med. 2003;9:269–277.

<|ref|>text<|/ref|><|det|>[[58, 826, 477, 845]]<|/det|>
3. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278–287.

<|ref|>text<|/ref|><|det|>[[58, 846, 477, 875]]<|/det|>
4. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239–245.

<|ref|>text<|/ref|><|det|>[[58, 876, 477, 905]]<|/det|>
5. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18:6580–9587.

<|ref|>text<|/ref|><|det|>[[58, 906, 477, 926]]<|/det|>
6. Grosso J, Inzunza D, Wu Q, et al. Programmed death-ligand 1 (PD-L1) expression in various tumor types. J Immunother Cancer. 2013;1:53.

<|ref|>text<|/ref|><|det|>[[509, 82, 928, 102]]<|/det|>
7. Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol. 2015;11:1307–1326.

<|ref|>text<|/ref|><|det|>[[508, 103, 928, 122]]<|/det|>
8. Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7:97–106.

<|ref|>text<|/ref|><|det|>[[508, 123, 928, 142]]<|/det|>
9. Sundar R, Cho BC, Brahmer JR, Soo RA. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7:85–96.

<|ref|>text<|/ref|><|det|>[[505, 143, 928, 182]]<|/det|>
10. Berman D, Korman A, Peck R, Feltgate D, Lonberg N, Canetta R. The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience. Pharmacol Ther. 2015;148c:132–153.

<|ref|>text<|/ref|><|det|>[[505, 183, 927, 203]]<|/det|>
11. Sondak VK, Smalley KSM, Kudchadkar R, Gripston S, Kirkpatrick P, Ipilimumab. Nat Rev Drug Discov. 2011;10:411–412.

<|ref|>text<|/ref|><|det|>[[505, 203, 927, 223]]<|/det|>
12. Phillips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 2015;27:39–46.

<|ref|>text<|/ref|><|det|>[[505, 223, 928, 243]]<|/det|>
13. Deri MA, Zeglis BM, Francesconi LC, Lewis JS. PET imaging with  \( {}^{89} \) Zr: from radiochemistry to the clinic. Nucl Med Biol. 2013;40:3–14.

<|ref|>text<|/ref|><|det|>[[505, 243, 927, 262]]<|/det|>
14. Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev. 2014;43:260–290.

<|ref|>text<|/ref|><|det|>[[505, 263, 928, 292]]<|/det|>
15. Braghirolli AMS, Waissmann W, da Silva JB, dos Santos GR. Production of iodine-124 and its applications in nuclear medicine. Appl Radiat Isot. 2014;90:138–148.

<|ref|>text<|/ref|><|det|>[[505, 293, 928, 323]]<|/det|>
16. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110:2858–2902.

<|ref|>text<|/ref|><|det|>[[505, 323, 928, 353]]<|/det|>
17. Fischer G, Seibold U, Schirrmacher R, Wangler B, Wangler C, Zr-89, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges. Molecules. 2013;18:6469–6490.

<|ref|>text<|/ref|><|det|>[[505, 353, 927, 373]]<|/det|>
18. Zhang Y, Hong H, Cai W. PET tracers based on zirconium-89. Curr Radiopharm. 2011;4:131–139.

<|ref|>text<|/ref|><|det|>[[505, 374, 928, 404]]<|/det|>
19. Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2:846–856.

<|ref|>text<|/ref|><|det|>[[505, 404, 928, 433]]<|/det|>
20. Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA.  \( {}^{89} \) Zr immuno-PET: comprehensive procedures for the production of  \( {}^{89} \) Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271–1281.

<|ref|>text<|/ref|><|det|>[[505, 433, 928, 454]]<|/det|>
21. Tinianow JN, Gill HS, Ogasawara A, et al. Site-specifically  \( {}^{89} \) Zr-labeled monoclonal antibodies for ImmunoPET. Nuc Med Biol. 2010;37:289–297.

<|ref|>text<|/ref|><|det|>[[505, 454, 928, 483]]<|/det|>
22. van Dongen GA, Vosjan JM. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm. 2010;25:375–385.

<|ref|>text<|/ref|><|det|>[[505, 483, 928, 504]]<|/det|>
23. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov. 2008;7:591–607.

<|ref|>text<|/ref|><|det|>[[505, 504, 928, 523]]<|/det|>
24. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature. 2008;452:580–589.

<|ref|>text<|/ref|><|det|>[[505, 524, 928, 564]]<|/det|>
25. Lamberts LE, Williams SP, Terwisscha van Scheltinga AG, Lub-de Hooge MN, Schroder CP, Gietema JA, Brouwers AH, de Vries EG. Antibody positron emission tomography imaging in anticancer drug development. J Clin Oncol. 2015;33:1491–1504.

<|ref|>text<|/ref|><|det|>[[505, 564, 928, 604]]<|/det|>
26. Jauw YW, Menke-van der Houven van Oordt CW, Hoekstra OS, Hendrikse NH, Vugts DJ, Zijlstra JM, Huisman MC, van Dongen GA. Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials. Front Pharmacol. 2016;7:131.

<|ref|>text<|/ref|><|det|>[[505, 605, 928, 625]]<|/det|>
27. Ni YG, Yuan X, Newitt JA, et al. Development and fit-for-purpose validation of a soluble human programmed death-1 protein assay. AAPs J, 2015;17:976–987.

<|ref|>text<|/ref|><|det|>[[505, 625, 928, 664]]<|/det|>
28. Vosjan MJWD, Perk LR, Visser GWM, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatophenyl-desferrioxamine. Nat Protoc. 2010;5:739–743.

<|ref|>text<|/ref|><|det|>[[505, 664, 928, 684]]<|/det|>
29. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131–137.

<|ref|>text<|/ref|><|det|>[[505, 684, 928, 724]]<|/det|>
30. Meares CF, McCall MJ, Reardon DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem. 1984;142:68–78.

<|ref|>text<|/ref|><|det|>[[505, 725, 928, 744]]<|/det|>
31. Marquez BV, Ikotun OF, Zheleznyak A, et al. Evaluation of  \( {}^{89} \) Zr-pertuzumab in breast cancer xenografts. Mol Pharm. 2014;11:3988–3995.

<|ref|>text<|/ref|><|det|>[[505, 745, 928, 774]]<|/det|>
32. Holland JP, Caldas-Lopes E, Divilov V, et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PloS One. 2010;5:e8859.

<|ref|>text<|/ref|><|det|>[[505, 775, 928, 794]]<|/det|>
33. Abou DS, Ku T, Smith-Jones PM. In vivo biodistribution and accumulation of  \( {}^{89} \) Zr in mice. Nuc Med Biol. 2011;38:675–681.

<|ref|>text<|/ref|><|det|>[[505, 795, 928, 824]]<|/det|>
34. Cogswell JP, Goldberg SM, Gupta AK, Jure-Kunkel M, Wang XT, Wigginot JM. Cancer immunotherapy by disrupting PD-1/PD-11 signaling. Bristol-Myers Squibb Co. WO2013173223 A1.

<|ref|>text<|/ref|><|det|>[[505, 825, 928, 845]]<|/det|>
35. Deri MA, Ponnala S, Kozlowski P, et al. P-SCN-B-HOPO: a superior bifunctional chelator for  \( {}^{89} \) Zr immunoPET. Bioconjug Chem. 2015;26:2579–2591.

<|ref|>text<|/ref|><|det|>[[505, 845, 928, 884]]<|/det|>
36. Vugts DJ, Klaver C, Sewing C, et al. Comparison of the octantedate bifunctional chelator DFO-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for  \( {}^{89} \) Zr-immuno-PET. Eur J Nucl Med Mol Imag. 2017;44:286–295.

<|ref|>text<|/ref|><|det|>[[505, 885, 928, 925]]<|/det|>
37. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–3175.